GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (OCSE:GUBRA) » Definitions » Other Gross PPE

Gubra AS (OCSE:GUBRA) Other Gross PPE : kr77.7 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Other Gross PPE?

Gubra AS's Other Gross PPE for the quarter that ended in Dec. 2024 was kr77.7 Mil.

Gubra AS's quarterly Other Gross PPE increased from Dec. 2023 (kr52.5 Mil) to Jun. 2024 (kr96.1 Mil) but then declined from Jun. 2024 (kr96.1 Mil) to Dec. 2024 (kr77.7 Mil).

Gubra AS's annual Other Gross PPE increased from Dec. 2022 (kr50.6 Mil) to Dec. 2023 (kr52.5 Mil) and increased from Dec. 2023 (kr52.5 Mil) to Dec. 2024 (kr77.7 Mil).


Gubra AS Other Gross PPE Historical Data

The historical data trend for Gubra AS's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Other Gross PPE Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Gross PPE
Get a 7-Day Free Trial 79.81 80.31 50.64 52.53 77.73

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only 50.64 62.47 52.53 96.15 77.73

Gubra AS Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Gubra AS Business Description

Traded in Other Exchanges
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.

Gubra AS Headlines

No Headlines